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Abstract: Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern
therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional
disease of the peritoneal cavity by breaking immune tolerance. These strategies include heightening
T-cell response and vaccine induction of anti-cancer memory against tumor-associated antigens.
Early investigations with chimeric antigen receptor T cells (CAR-T cells), vaccine-based therapies,
dendritic cells (DCs) in combination with pro-inflammatory cytokines and natural killer cells
(NKs), adoptive cell transfer, and immune checkpoint inhibitors represent significant advances
in the treatment of PM. IP delivery of CAR-T cells has shown demonstrable suppression of tumors
expressing carcinoembryonic antigen. This response was enhanced when IP injected CAR-T cells were
combined with anti-PD-L1 or anti-Gr1. Similarly, CAR-T cells against folate receptor α expressing
tumors improved T-cell tumor localization and survival when combined with CD137 co-stimulatory
signaling. Moreover, IP immunotherapy with catumaxomab, a trifunctional antibody approved in
Europe, targets epithelial cell adhesion molecule (EpCAM) and has shown considerable promise with
control of malignant ascites. Herein, we discuss immunologic approaches under investigation for
treatment of PM.
Keywords: intraperitoneal immunotherapy; vaccines; CAR-T cells; ascites; carcinoembryonic antigen;
folate receptor α; dendritic cells; peritoneal; metastasis
1. Introduction
Peritoneal surface malignancies and peritoneal metastasis (PM) develop from a broad spectrum
of primary and metastatic malignancies [1,2]. First described in 1899, PM typically leads to symptoms
of malignant obstruction and significant tumor burden leaving palliative treatment options and
dismal patient outcomes, not exceeding 2 to 6 months (Figure 1) [2–6]. Treatment with systemic
chemotherapy, although improving patient outcomes, leads to survival rates ranging between
6.4–17.9 months [2]. Throughout history to current practice, peritoneal disease recurrence after surgery
remains high [7,8], resulting in treatment strategies that advocate for aggressive surgical approaches
such as tumor debulking and cytoreduction combined with perioperative systemic and intraperitoneal
(IP) chemotherapy [9–12].
Vaccines 2018, 6, 54; doi:10.3390/vaccines6030054 www.mdpi.com/journal/vaccines
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Improved survival of cancer patients with PM treated with heated IP chemotherapy (HIPEC)
was previously demonstrated in clinical trials conducted in the 1980s [10–12]. Recently, the potential
benefit of combined cytoreduction and HIPEC was shown by Verwaal and colleagues in patients with
colorectal peritoneal metastasis. They cited nearly doubling of 2 year survival rates beyond standard
therapy [13–15]. However, for colorectal and other peritoneal surface malignancies, the majority
of clinical studies are plagued by continued high rates of peritoneal recurrence and poor patient
survival [16–18]. The burgeoning use of immunotherapy in the management of metastatic malignancies
has led to investigations into translational applications for both primary and metastatic regional
peritoneal disease [1].
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Figure 1. (A) Abdominal peritoneal metastasis from ovarian cancer. White arrows demonstrate 
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2. Immunotherapeutic Breakthroughs in the Modern Era 
Several breakthroughs led to historic achievements in the field of immunotherapy. Notably, the 
concept of immunosurveillance, by Burnet and Thomas, proposing the immune system’s ability to 
recognize cancer cells that could prevent the development of cancer and multifactorial determinants 
of ‘tumor immunity’ [19,20]. This understanding led to innovative immunotherapeutic approaches 
to trigger anticancer immune responses [21]. Subsequent advancements largely evolved from Lloyd 
J. Old‘s contributions and seminal discovery of the tuberculosis Bacille Calmette-Guerin (BCG) 
vaccine and tumor necrosis factor [22,23], and Thierry Boon’s observation of immune recognition by 
T-cells of mutagen-altered tumor antigens [24]. Alan N. Houghton cloned melanoma differentiation 
antigen-tyrosinase, identified tyrosinase-related protein-1 as the target for monoclonal antibody TA-
99, and developed xenogeneic orthologs of self-antigens, ‘altered self,’ which is now widely 
recognized as a means of breaking immune ignorance and tolerance to poorly immunogenic targets 
on cancer cells [25–33]. Pioneering work by Ralph M. Steinman led to the discovery and central role 
of the dendritic cell with its inherent ability to present antigens to T cells, acting as an important 
accessory cell in the development of antigen-specific immune responses [34,35].  
Immunotherapeutic investigations by Steven A. Rosenberg brought further discoveries utilizing 
lymphokine-activated killer cells and interleukin 2 (IL-2) , and genetically modified T-cells encoding 
receptors specific for tumor antigens. Rosenberg’s contributions would later become the foundation 
of treatment for melanoma and other metastatic malignancies [36–39]. Further advances include the 
discovery of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) by James P. Allison and 
colleagues’ [40,41], and Gordon J. Freeman’s description of a second pathway of immune inhibition, 
the programmed death-1 receptor (PD-1) [42,43]. Immune checkpoint inhibitors blocking these 
pathways led to downregulation of T-cell activation tested as monotherapy and polytherapy for 
melanoma, renal cell carcinoma and lung cancer [44]. 
  
 
Figure 1. (A) Abdominal peritoneal metastasis from ovarian cancer. White arrows demonstrate
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2. Immunotherapeutic Breakthroughs in the Modern Era
Several breakthroughs led to historic achievements in the field of immunotherapy. Notably, the
concept of immunosurveillance, by Burnet and Thomas, proposing the immune system’s ability to
recognize cancer cells that could prevent the development of cancer and multifactorial determinants of
‘tumor immunity’ [19,20]. This understanding led to innovative immunotherapeutic approaches
to trigger anticancer immune responses [21]. Subsequent advancements largely evolved from
Lloyd J. Old‘s contributions and seminal discovery of the tuberculosis Bacille Calmette-Guerin (BCG)
vaccine and tumor necrosis factor [22,23], and Thierry Boon’s observation of immune recognition by
T-cells of mutagen-altered tumor antigens [24]. Alan N. Houghton cloned melanoma differentiation
antigen-tyrosinase, identified tyrosinase-related protein-1 as the target for monoclonal antibody TA-99,
and developed xenogeneic orthologs of self-antigens, ‘altered self,’ which is now widely recognized
as a means of breaking immune ignorance and tolerance to poorly immunogenic targets on cancer
cells [25–33]. Pioneering work by Ralph M. Steinman led to the discovery and central role of the
dendritic cell with its inherent ability to present antigens to T cells, acting as an important accessory
cell in the development of antigen-specific immune responses [34,35].
Immu otherapeutic investigations by Steve A. Rosenberg brought further discoveries utilizing
lymphokine-a tivated killer cells and interleukin 2 (IL-2) , and genetically modified T-c lls e coding
receptors specific for tumor tigens. Rosenberg’s contributions would later become the foun ation
of treatment or melanoma and other metast ic malignancies [36–39]. Further advance i clude
the discovery of cytotoxic T-lymphocyte-a sociated protein 4 (CTLA-4) b Ja es P. Allison a d
coll agues’ [40,41], and Gordon J. F eeman’s description of a second pathway of immune hibition,
the programmed eath-1 receptor (PD-1) [42,43]. Immune checkp int inhibitors b ocking these
pathways led to downregulation of T-cell activation tested as monotherapy and polytherapy for
melanoma, renal cell carcinoma and lung cancer [44].
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3. CAR-T Cell Immunotherapy
CAR-T technology developed by Carl H. June, redirects patient-derived T cells engineered for
cancer antigen-specific targeting, with minimal systemic toxicity [45]. Success of CAR-T technology
in clinical trials for hematologic malignancies has led to further investigation of its role in treatment
of refractory stage IV solid tumors. The main component of a CAR-T cell is an extracellular single
chain variable fragment (scFv) from antibodies specific to the cancer antigen of interest and T-cell
activating domain. The scFv component of CAR-T cells confers an advantage over specific T-cell
therapy, designating CAR-Ts MHC independent [46,47]. A means to induce tumor immunity has
been demonstrated using CAR-T cells for solid tumor malignancies. Carcinoembryonic antigen (CEA)
has been a target for the development of CAR-T cells against gastric, colorectal, and breast cancers
due to its overexpression in solid tumors when compared to normal cells [48]. This novel treatment
paradigm has been applied towards metastatic malignancies evidenced by studies directed against
hepatic metastasis from colorectal cancer [49]. It has been shown by Parkhurst and colleagues that
anti-CEA CAR-T cells proliferate in response to tumors overexpressing CEA, resulting in IL-2 and
IFNγ cytokine secretion and tumor cell lysis. Although remarkable, systemic administration of CAR-T
cells was associated with severe toxicity limiting its clinical utility [50].
Katz and colleagues found that regional delivery anti-CEA CAR-T cells via hepatic artery infusion,
reduced immune-mediated damage to CEA expressing cells by specifically targeting tumor metastasis
to the liver [49]. In their phase I study, two cohorts of three patients each received CAR-T infusions,
with one group also receiving supplemental IL-2 infusions. Importantly, they reported no grade four or
five events after administering maximal CAR-T dosage with a single patient living 54 months following
hepatic artery CAR-T infusion. In addition, they found elevated serum IFNγ, closely corresponding
to significant decreases in CEA in the IL-2 treatment group. These findings were corroborated with
image-guided core biopsies showing targeted tumor necrosis and fibrosis as well as preferential CAR-T
cell localization to tumors on immunohistochemistry while normal parenchyma was spared [1,49].
Despite advances in regional delivery of CAR-T cells, challenges remain in the immunotherapeutic
application of CAR-T cells due to immunosuppressive pathways inherent to solid tumors.
Immunosuppression is driven by high levels of the immune checkpoint molecule programmed cell
death-ligand (PD-L) as shown in advanced pancreatic, breast, and ovarian cancer. Similarly, activation
of T lymphocyte in malignant ascites from ovarian cancer is further suppressed by the presence
of PD1/ PD-L1 or B7/H1, the CD274 pathway, or the T cell immunoglobulin and mucin domain
containing 3 (TIM3)/ galectin9 pathway [51,52]. Additionally, immunosuppression can also be driven
by granulocyte macrophage colony stimulating factor (GM-CSF) and CD4+ Fox3+ CD25+ T regulatory
cells (Tregs) which are upregulated in pancreatic ductal adenocarcinoma. GM-CSF is produced by
pancreatic ductal epithelial cells (PDECs) bearing an oncogenic KrasG12D allele and inhibits anti-cancer
activity of CAR-Ts via recruitment and proliferation/maturation of Gr-1+ CD11b+ myeloid derived
suppressor cells (MDSCs) in lymphoid organs. MDSCs produce nitric oxide (NO) and deplete arginine
in the environment to induce apoptosis of T-cells. Thus, suppression of either GM-CSF or MDSCs in
combination with immunotherapy can be a potential strategy to reduce tumor burden in patients with
PM [53–55].
Another surface antigen widely targeted in ovarian, breast, and colorectal cancers by CAR-T
therapy is a glycosylphosphatidylinositol-anchored protein, FRα. FRα is localized to the luminal
side of polarized epithelial cells in normal tissue, while it is upregulated in tumor cells, losing its
polarization. Thus, FRα not exposed to the circulation in normal tissue is accessible to circulation in
the setting of malignancy, allowing for tumor-specific targeting by intravenously delivered CAR-T
cells [56]. However, there have been initial setbacks with first generation MOv-19ζ CAR-T cells
targeting FRα containing CD3ζ intracellular signaling faltering in clinical trials, due to inconsistent
localization to tumor sites [57].
Additionally, the harsh tumor microenvironment (low in oxygen and nutrients) poses a challenge
for proliferation and survival of CAR-T cells. Moreover, adverse events such as neurotoxicity, cytokine
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release syndrome, and tumor lysis syndrome leading to hyperkalemia and hyperuricemia have
been reported in clinical trials of CAR-T cell treatment [48]. T cell activation and survival is further
jeopardized by glucose and glutamine-depleted tumor microenvironments. Enrichment of CAR-T
cells can be optimized by co-stimulatory signals; CD28 which promotes aerobic glycolysis and 4-1BB
by enhancing fatty acid oxidation as well as mitochondrial biogenesis. These signals also promote
effector memory T cells and prolong CAR-T cell survival in circulation [45,58].
4. CAR-T Cell Investigations for Peritoneal Metastasis
Advancements in our understanding of the tumor microenvironment has led to developments in
CAR-T cell technology with direct intraperitoneal application for treatment of PM (Table 1). T cells
expressing chimeric antigen receptor (CAR) gene specific to tumor-associated antigens (TAA’s) are
regionally delivered to the peritoneal cavity enhancing CAR-T delivery to the site of the disease
avoiding on-target off tumor effects, in addition to mitigating or eliminating cytokine release syndrome
and neurotoxicity (Figure 2). We now recognize that the route of CAR-T cell administration significantly
impacts tumor localization and regression. Katz et al. introduced regional, hepatic artery infusion of
CAR-T cells to treat hepatic tumors from metastatic colorectal cancer [49]. They further investigated the
effects of IP vs systemically delivered anti-CEA CAR-T cells in a C57BL6 murine colon adenocarcinoma
model. MC38 expressing CEA, which are C57BL6 murine colon adenocarcinoma-derived cells, were
cultured with either untransduced or anti-CEA CAR-T cells derived from murine splenic T cells
activated by IL-2 prior to culturing. Treatment with CAR-T cells resulted in significant MC38CEA cell
lysis as compared to normal splenic T cells. A 37-fold tumor reduction was noted in mice receiving
anti-CEA CAR-T cells IP as compared to only three fold tumor reduction in mice receiving anti-CEA
CAR-T cells by tail vein injection. This treatment effect was further pronounced when anti-CEA
CAR-Ts were delivered in combination with anti-PD-L1 or anti-Gr1 antibodies suppressing MDSCs
and Tregs. Furthermore, in response to CAR-T treatment, endogenous T cells shifted to effector
memory T cell phenotype (with phenotype CD44+CD62L-CCR7-), which was evident after 28 days
as compared to day 10. Moreover, 4 days after IP infusions of anti-CEA CAR-T cells with daily IL-2
injections, a significant increase of systemic IFNγ levels was detected. These preclinical results provide
evidence for the potential of combinatory therapy to overcome peritoneal metastasis [59]. Anti-CEA
CAR-T cells, given systemically, are now under investigation and currently accruing patients in phase
I clinical trials for gastric, colorectal and breast cancer (NCT02349724) [48].
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Figure 2. T cells are expanded from peripheral blood mononuclear cells (PBMCs) and transduced with
a vector containing the chimeric antigen receptor (CAR) gene. T cells expressing CARs (CAR-T cells)
specific for tumor-associated antigens (TAAs) are delivered to the patient intraperitoneally to maximize
delivery to the site of disease while minimizing systemic exposure and toxicity.
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Table 1. CAR-T cell therapy for peritoneal metastasis.
Cancer Type Treatment Target Model Author (Year)
Gastric and Ovarian chA21-4-1BBz CAR-T cells HER2 Murine Han et al. [60] (2018)
Ovarian cancer CE7+R TCM CAR-T cells L1-CAM Murine
Hong et al. [61] (2016)
Daponte et al. [62]
(2008)
Colorectal cancer Anti CEA CAR-T cells withanti Gr1/GITR and anti PD-L1
CEA, Gr1 and
PD-L1 Murine Katz et al. [59] (2016)
Ovarian cancer Anti MUC16 CAR-T cells MUC16 Human Koneru et al. [63,64](2015)
Breast and gastric
cancer Anti CEA CAR-T cells CEA Human NCT02349724 (2015)
Ovarian, Breast and
Colorectal cancer Anti FRα CAR-T cells FRα Murine Song et al. [57] (2011)
Abbreviations: PM, peritoneal metastasis; CAR-T, chimeric antigen receptor expressing T cells; CEA,
carcinoembryonic antigen; PD-L1, programmed cell death protein-ligand 1; MUC16, mucin 16 associated with
membrane; FRα, folate receptor α; HER2, human epidermal growth factor receptor 2; L1-CAM, L1 cell adhesion
molecule; NCT, national clinical trial identifier.
Through further investigations, Song et al. demonstrated that regional administration of second
generation CAR-T cells promotes long term anti-FRα CAR-T cell persistence and tumor localization.
These second generation CAR-T cells were generated by the incorporation of a co-stimulatory
signal, CD137, into first generation MOv-19ζ CAR-T cells. CD137 allows for the persistence of
memory T cells and CD8+ T cells. Furthermore, CD137 promotes expression of BCl-XL, which
confers resistance to apoptosis and prolongs survival [57]. Han et al. incorporated CD137 (4-1BB) in
chA21 CAR-T cells to create second generation chA21-4-1BBz CAR-T cells highly specific for cells
overexpressing human epidermal growth factor receptor 2 (HER2) (i.e., SKOV3—human ovarian
cancer, and NCI-N87—human gastric cancer). In a NOD-SCID mouse xenograft model, treatment with
chA21-4-1BBz CAR-T cells resulted in an improved half-life and greater accumulation of CAR-T cells
at the tumor site. In addition, second generation CAR-T cell therapy appreciably reduced ascites and
tumor burden in this mouse model [60]. Another strategy to increase CAR-T cell localization is the use
of endothelin inhibitors to prevent tumor migration [47,57].
CAR-T cells have been investigated in ovarian cancer where novel treatment options are sought
due to the presence of advanced stages at diagnosis. Koneru et al. targeted the extracellular domain
of MUC16 (MUC-16ecto) which is upregulated in advanced stage ovarian cancer. They constructed
anti-MUC-16ecto CAR-T cells co-expressing IL-12 in order to ensure activation and proliferation of
these CAR-Ts at the tumor site in the presence of immune checkpoints. These CAR-Ts, when delivered
IP in a SCID Beige ovarian cancer xenograft model, were more effective in enhancing tumor reduction
and survival in mice as compared to anti- MUC-16ecto CAR-T cells with no IL-12 arm [63].
Another CAR-T platform-derived T cell with chimeric antigen receptor CE7R (CE7+R TCM) against
the CE7 epitope of L1 cell adhesion molecule (L1-CAM) was investigated in a human ovarian cancer
(SKOV3) xenograft PM model by Hong et al. [61]. This mouse model used IP injections of SKOV3
cells into NOD/scid-IL2Rγnull (NSG) mice, resulting in large volume malignant ascites. L1-CAM
was chosen as a potential target for its role in ovarian tumor progression and development of drug
resistance. CE7+R TCM treatment demonstrated a significant reduction in tumor burden with no
detectable ascites. However, T cells against L1-CAM could not prevent tumor recurrence due to the
subsequent loss of L1-CAM expression in residual disease. Importantly, combination of CE7+R TCM
cells with CAR-T cells targeting other antigens may improve the efficiency of this treatment [61,62].
5. Cancer Vaccines for Peritoneal Metastasis
Immunotherapy cancer vaccines have been an area of much interest for decades with significant
advances being tailored towards IP treatment of peritoneal metastasis (Table 2 and Figure 3). Malignant
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ascites poses a major obstacle in evoking an immune response to vaccines. To target ascites, DCs
have been combined with cytokine-induced killer cells (CIKs), which are cytotoxic T lymphocytes
with CD3+ CD56+ phenotype. CIKs were chosen for three important reasons: they are minimally
cytotoxic towards normal cells, they do not negatively impact hematopoiesis in bone marrow, and
they are resistant to apoptosis mediated by Fas ligand. Combination therapy of DCs and CIKs has
resulted in the reduction of immunosuppressive Tregs and the accumulation of cytotoxic T cells in
ascites, mediated by TNFα and IFNγ [65]. As with CAR-T cells, the mode of administration is of
paramount importance in the delivery of cancer vaccines. Natural killer cells (NKs) have proven to
be excellent anti-tumor agents, eliciting a strong immune response when combined with DCs. Geller
et al. demonstrated that IP delivered NK cells activated by IL-2 improved anti-tumor effects in an
ovarian cancer xenograft mouse model compared to systemic delivery [66]. Additionally, Oyer et al.
demonstrated that the half-life of IP delivered NK cells in vivo and accumulation at tumor site can be
enhanced by PM21 particles which are derived from the plasma membrane of K562-mb21-41BBL cells
and membrane bound IL-21 in hematologic malignancies. Moreover, treatment with PM21 resulted in
significant activation and proliferation of human NK cells in spleen, lung and bone marrow supporting
use as a potential therapy for malignancies in the peritoneal cavity [67,68].
Table 2. Cancer vaccines for peritoneal metastasis.
Cancer Type Treatment Target Model Author (Year)
Ovarian cancer,
peritoneal
carcinomatosis
GL-ONC1 Malignant ascites Human Lauer et al. [69] (2018)
Colon cancer MG1-IL12-ICV CD69 and IP10 Murine Alkayyal et al. [70] (2017)
Colon cancer
FRα targeted
lipoplex delivering
IL-15 gene.
FRα Murine Liang et al. [71] (2016)
Colon and breast
Anti PD-L1 and
CTLA-4 in
combination with
IL-18
PD-L1 and CTLA-4 Murine Ma et al. [72] (2016)
Chronic
myelogenous
leukemia
NK cells
stimulated by IL-21 NKs Murine Oyer et al. [68] (2016)
Ovarian cancer,
peritoneal
metastasis
Survivac vaccine Survivin Human Berinstein et al. [73] (2015)
Colon, ovarian,
gastric, pancreatic
cancer
Dendritic cell
vaccine+CIKs
Tumor inducing
cytokines,
CD4+CD25+Tregs
Human Ai et al. [65] (2014)
Ovarian cancer Reovirus basedanti-cancer therapy
Gr 1.1+,
CD11b+MDSCs,
FOXP3+Tregs,
CD3+cells.
Human,
Murine Gujar et al. [74] (2013)
Ovarian cancer IP deliveredhuman NKs Murine Geller et al. [66] (2013)
Ovarian cancer Anti MUC1 T cells MUC1 Human Dobrzanski et al. [75] (2009)
Ovarian cancer Multipeptidevaccine
MAGE-A1, FBP,
Her-2/neu Human
Chianene-Bullock et al. [76]
(2008)
Abbreviations: MDSCs, myeloid derived suppressor cells; IP10, IFNγ-induced protein 10; FRα, folate receptor α;
IL-15, interleukin-15; PD-L1, programmed cell death protein-ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated
protein 4 Tregs, T regulatory cells; CIK, cytokine induced killer cells; MG1-IL12-ICV, Maraba virus MG1 with
interleukin 12-infected cell vaccine; IP, intraperitoneal; NKs, natural killer cells; IL-21, interleukin 21; MUC1, mucin1;
MAGE-A1, melanoma associated antigen-A1; FBP, folate binding protein;.
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Figure 3. Dendritic cells (DC ) derived from the isolated patient peripheral blo onuclear cells
(PBMCs) are cultured with tumor-associated antigen(s) (TA ) of interest w i e from whole
tumor cells, recombinant virus with tumor antigen DNA or peptide-pulsed. The efficiency of anti-tumor
activity is further enhanced when DCs are delivered in combination with natural killer cells (NKs),
cytokine-induced killer cells (CIKs) and inhibitors of immune checkpoints (anti CTLA-4 and anti
PD-1/PDL-1). Another strategy involves in vitro expansion and IP delivery of CD4+ T helper cells.
Alkayyal et al. later showed the importance f combini g ro-infl mmatory cytokine IL-12
with oncolytic virus (Maraba MG1) in reducing tum r burden in a peritoneal metastatic colon cancer
murine model by inoculation of CT26 (murine colon cancer cells) into Balb/c mice. MG1-IL12-ICV,
delivered IP significantly decreased tumor size in these mice, established resistance to re-inoculation
by CT26 cells and improved survival. Mechanistically, IL-12 was capable of activating and recruiting
NK cells to the tumor site for eradication. These activated NK cells secreted IFNγ, which together with
MG1 viral proteins, stimulated DCs leading to further NK cell recruitment [70]. Ma et al. assessed
the importance of combination of IP delivered antibodies against αCTLA-4 and αPD-L1 with IL-18
in BALB/c mice injected IP with CT26 nd 4T1 (mouse breast carcinoma cells). Mice receiving IP
infusions of anti-αCTLA-4 and anti-αPD-L1 had a survival advantage over mice receiving tail vein
injections. Survival was further prolonged in mice receiving IP antibody therapy al g with IL-18
as this cytokine resulted in recruitment of NK and CD8+ T cells accompanied with decrease in Tregs
in the peritoneal cavity [72,77]. Furthermore, Dobrzanski et al. demonstrated that multiple cycles of
IP-delivered patient-derived type I CD4+ T helper cells (Th1) with cytokines IL-2 and IFNγ, enhanced
the anti-tumor activity of autologous CD8+ T cells against the tumor-specific glycoform of MUC1 in
ovarian cancer patients [75,78].
Malignant ascites leads to poor prognosis and vaccines are being developed and modified to target
ascites in an attempt to improve the quality of life in patients w th PM. Ai and colleagues evaluated
the safety and efficacy of IP-delivered dendritic cell vaccine in combination with CIKs in pati nts with
malignant ascites. This vaccine was well tolerated and resulted in a significant i provement in the
quality of life of these patients. IP delivery of this DC vaccine resulted in expansion and cytotoxic
activity of CD3+ CD56+ CIKs and a decrease in Tregs. Moreover, this treatment induced the production
of IFNγ capable of blocking angiogenesis and metastasis in cancer cells [65,79].
Reovirus-based anticancer treatment is now an option in patients with PM resistance to current
chemotherapies as this method is capable of overcoming immunosuppression by activating DCs
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and eventually leading to intrinsic anti-tumor T cell activity [74]. A study by Gujar et al. employed
reovirus-based immunotherapy in a PM murine model developed by injecting female C57BL/6 mice
with ID8 (mouse ovarian carcinoma cells). This virotherapy resulted in prolonged survival and
delayed PM development in mice along with decrease in Tregs and MDSCs, increase in CD3+ and
CD8+ Tlymphocytes and induction of Th1 cytokine, IFNγ [80]. Reovirus-based therapy has completed
clinical trials for various malignancies worldwide including US, UK and Canada. It has completed
a phase I study for primary peritoneal cancer and undergone a phase II study for patients with
recurrent ovarian and primary peritoneal cancer (NCT01199263, NCT00602277) [81]. Recently, another
virus-based immunotherapy, GFP and β glucuronidase in a oncolytic vaccinia virus (GL-ONC1)
developed for patients with PM, completed accrual in a non-randomized phase I clinical trial. This
vaccinia virus-based vaccine presented a safe profile when delivering IP and successfully established
viral infection and replication specifically in ascitic fluid. The vaccine also induced lysis of cancer cells
confirmed by the release of GL-ONC1 encoded transgenic β-glucuronidase after oncolysis [69].
Heterogeneity in tumor cells and loss of antigenicity in residual tumors after treatment makes
immunotherapy to prevent disease progression and recurrence challenging. In order to address this
issue, Chianene-Bullock et al. tested the efficacy and tolerability of a multi-peptide vaccine containing
five epitopes in patients with ovarian cancer, and fallopian tube and peritoneal cancer. These five
epitopes were derived from melanoma differentiation antigen-A1 (MAGE-A1), folate binding protein
(FBP) and Her-2/neu which are found in abnormally high levels on ovarian cancer cells. The five
epitopes were restricted by human leukocyte antigen (HLA)-A1, A2, A3. Based on this, the vaccine was
delivered to patients positive for HLA-A1, A2 and A3 in combination with GM-CSF and montanide
ISA-51 adjuvant. Stimulation of T cell activity was detected in eight out of nine patients and the
multi-peptide vaccine demonstrated a safe profile in these patients. However, due to poor T cell
response, combination of multi-peptide vaccine with immune checkpoint inhibitors and immune
modulators should be considered [76].
As previously mentioned, FRα is overexpressed in colon tumors and plays a major role in cancer
progression leading to poor survival in patients with PM [82]. A CT26 murine colon cancer model
was used by Liang et al. to evaluate the anticancer activity of an IP administered FRα targeted
liposome-based recombinant IL-15 plasmid (F-PLP/pIL15). Treatment with F-PLP/pIL15 significantly
increased the expression of IL-15 in circulation and in ascites leading to substantial tumor reduction
via activation of NKs and CD8+ T cells. Based on this antitumor efficacy, IL-15 can be a promising
cytokine therapy for patients with unresectable PM [71,83].
6. Catumaxomab
The trifunctional antibody is an emerging platform capable of producing a long-term vaccination
effect. In 2009, catumaxomab became the first drug approved in Europe for treating malignant
ascites associated with peritoneal carcinomatosis [84]. IP administration of this bispecific monoclonal
antibody has demonstrated a safe profile in clinical trials and is capable of targeting both innate and
adaptive immune systems (Table 3). The two antigen-binding sites of catumaxomab target CD3+
T-cells and EpCAM receptors while the fragment crystallizable (Fc) domain activates types I, IIa, and
III Fcγ-receptors on NK cells. This process leads to phagocytosis of the targeted tumor cells and cell
death by pro-apoptotic cytokines such as IL-2, IL-12, and TNF-α [85–87] (Figure 4).
Table 3. Trifunctional antibody for peritoneal metastasis.
Cancer Type Treatment Target Model Author (Year)
Gastric cancer
Intra and postoperatively
administered
Catumaxomab
EpCAM Human Bokemeyer et al. [88] (2015)
Colorectal cancer Catumaxomab EpCAM Human Borlak et al. [89] (2015)
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Table 3. Cont.
Cancer Type Treatment Target Model Author (Year)
Ovarian cancer Catumaxomab EpCAM Human Wimberger et al. [90] (2012)
Ovarian, pancreatic,
colon, gastric, breast Catumaxomab+paracentesis EpCAM Human Heiss et al. [86] (2010)
Gastric, ovarian, PM
ααom unknown
primary
Catumaxomab EpCAM Human StrÖhlein et al. [91] (2009)
Ovarian cancer Catumaxomab EpCAM Human Burges et al. [92] (2007)
Colon cancer Catumaxomab EpCAM Murine Ruf et al. [93] (2007)
Abbreviations: EpCAM, epithelial cell adhesion molecule.
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Figure 4. Catumaxomab, a trifunctional antibody contains three important binding sites: ne site
binds to the epithelial cell adhesion molecule (EpCAM) overexpressed on tumor cells and the second
site binds to CD3+ T cells. This bispecific antigen binding leads to apoptotic tumor lysis and the
resulting apoptotic bodies are phagocytosed. The third binding domain is fragment crystallizable (Fc)
which binds to types I, IIa, and III Fcγ-receptors on dendritic cells (DCs), natural killer cells (NKs) and
macrophages leading to direct phagocytosis of tumor cells . Furthermore, Fc binding to accessory cells
leads to the release of cytotoxic/ pro-apoptotic cytokines.
Peritoneal metastasis may be present upon diagnosis in many patients with ovarian cancer, with
a large volume of malignant ascites leading to distention and progressi n of disease. In a study by
Burges et l., 23 women with ovarian cancer were treated with catumaxom b for ascites refractory
to standard therapy. Treatment wi increasing doses of catumaxomab led to a significan reduction
in ascite production. Only 1 of the 23 treated patie s required pa acentesis 28 days after the last
infusion, which r mains almost 2 weeks longer th typicall required [92,94]. In a multice ter study
by Wimberger et al., 258 patients with ovarian and non-gynecologic malignancies were randomized to
treatment and control groups to determine the effect of catumaxomab therapy on quality of life [90].
Results were determined by patient questionnaires. Treatment with catumaxomab and paracentesis
significantly prolonged time to deterioration in quality of life as compared to paracentesis alone.
Similarly, a randomized multicenter trial by Heiss et al. compared paracentesis alone to paracentesis
with post-treatment IP infusion of catumaxomab in the management of malignant ascites from EpCAM+
malignancies. This phase II/III clinical trial randomized 258 patients and demonstrated significant
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improvements in median puncture-free survival and time-to-next-therapeutic-intervention in the
experimental group, and improved overall survival in patients with gastric cancer who received
catumaxomab [86].
Ströhlein et al. performed a compassionate use study in which nine patients with various
peritoneal surface malignancies were treated with escalating doses of catumaxomab via IP infusion [91].
While attempting to improve patient symptoms, the investigators also sought to determine the effect
of catumaxomab treatment on the development of long lasting tumor immunity. Tumor cells were
harvested during a patient’s initial surgery and were injected sub-dermally 4 weeks after the last
catumaxomab treatment. Five of nine patients demonstrated a significant increase in IFNγ producing
T cells (0.4% to 2.9%) and maintained these levels as long as 110 days after inoculation in one patient,
suggesting long-term immunity. Five of the nine patients also had stable or partial regression of
disease, with a mean overall survival of 11.8 months, compared to a mean survival of 6 months in the
EVOCAPE study by Sadeghi et al. [91,95]. Catumaxomab has also been shown to have a tolerable
toxicity profile in patients with resectable gastric cancer treated perioperatively [88]. Catumaxomab in
combination with paracentesis can be effective in treating malignant ascites and improving the overall
survival and quality of life of ovarian and gastric cancer patients [91,96].
Overall catumaxomab is well tolerated, with minimal systemic effects when delivered by IP [97].
However, a recent phase I clinical trial demonstrated a dose-dependent hepatotoxicity mediated by the
activation of anti-CD3 effector T cells by this trifunctional antibody [89,98]. Activation of these cells
led to off-target induction of hepatocytes. Of the 16 patients included in the initial study, one patient
suffered fulminant liver failure, leading to cessation of the trial. This study highlights the need for
further testing and monitoring of this treatment modality.
7. Conclusions
Peritoneal metastasis remains a lethal diagnosis despite modern treatment modalities which may
prolong survival. Recent investigations into the use of immunotherapy delivered as intraperitoneal
infusion represent a shift in the treatment paradigm for PM, towards treatment as a regional
disease rather than systemic metastasis. The use of chimeric T-cells, cell cycle checkpoint inhibitors,
tumor-specific antibodies, dendritic cell/tumor antigen vaccines, adoptive autologous T-cells,
virus-based vaccines and catumaxomab have shown early promise for management of peritoneal
metastasis. As a result, physicians will have more tools in their armamentarium to treat advanced
stage malignancies. Clinical studies into the use of intraperitoneal immunotherapy are underway and
this treatment strategy may reveal itself as the future treatment paradigm for peritoneal metastasis.
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